Active	Status	Sponsor type	Region	Phase	Filter
3 Active 20 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
deuterated S-lisofylline (PCS499) / Processa Pharma
NCT04800562: A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica	Terminated	2	4	US	PCS499, placebo	Processa Pharmaceuticals	Necrobiosis Lipoidica	02/23	04/23
NGC-capecitabine (PCS6422) / Processa Pharma
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Recruiting	2	90	US	PCS6422 and capecitabine, Capecitabine	Processa Pharmaceuticals	Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer	09/26	10/26
PCS6422-GI-01, NCT04861987: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors	Completed	1	23	US	PCS6422 and capecitabine	Processa Pharmaceuticals	Advanced Cancer, Refractory Cancer, Tumor Gastric	06/24	09/24
NGC-irinotecan (PCS-11T) / Processa Pharma
No trials found
PCS12852 / Processa Pharma
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
deuterated S-lisofylline (PCS499) / Processa Pharma
NCT04800562: A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica	Terminated	2	4	US	PCS499, placebo	Processa Pharmaceuticals	Necrobiosis Lipoidica	02/23	04/23
NGC-capecitabine (PCS6422) / Processa Pharma
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer	Recruiting	2	90	US	PCS6422 and capecitabine, Capecitabine	Processa Pharmaceuticals	Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer	09/26	10/26
PCS6422-GI-01, NCT04861987: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors	Completed	1	23	US	PCS6422 and capecitabine	Processa Pharmaceuticals	Advanced Cancer, Refractory Cancer, Tumor Gastric	06/24	09/24
NGC-irinotecan (PCS-11T) / Processa Pharma
No trials found
PCS12852 / Processa Pharma
No trials found